Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Essential Regulatory Solutions, Inc. is not a typical SaaS platform. It is closer to a regulatory affairs consulting and outsourced support provider for the pharmaceutical and medical product R&D sectors. The website highlights that its team has over 20 years of pharmaceutical industry experience and primarily serves small and mid-sized companies, helping clients supplement regulatory capabilities when workloads increase, staffing changes occur, or specific expertise is lacking. It also supports a wide range of regulatory activities across the product lifecycle, from development through registration submissions.
Its services cover a fairly complete regulatory affairs workflow, including development strategy, due diligence and gap analysis, regulatory representation/liaison, CMC/nonclinical/clinical expert support, preparation for scientific advice, pediatric study plans, Fast Track applications, and regulatory writing and review. Its writing scope includes 510(k), IND, IDE, NDA, MAA, PMA, clinical trial applications, orphan drug applications, Fast Track requests, clinical/nonclinical reports, study protocols, and investigator brochures.
For regulatory operations, Essential provides electronic document management, legacy document conversion, PDF pre-publishing, quality checks for bookmarks and internal document links, and creation of eCTD-compliant source files/templates. It can also create, compile, publish, maintain, and validate electronic submission dossiers in a validated Part 11 compliant publishing system, supporting submission processes in regions including the United States, the European Union, China, and Canada.
The website does not disclose any plans, pricing, subscription model, project-based fees, or free trial information. Based on the content, it is more likely to operate as a consulting service or project-based delivery provider, but this is not explicitly stated and therefore cannot be confirmed.
Its strengths are a clear experience background, coverage across multiple therapeutic areas and development stages, and the ability to either act as the regulatory lead for a project or provide supplementary strategic input to a client’s existing team. Its services are also relatively comprehensive, spanning strategy, writing, and electronic publishing/submission. The main drawback is the lack of standard SaaS product information: there are no details on account systems, workflows, permissions, third-party integrations, APIs, deployment options, or security certifications. Pricing and service boundaries are also not transparent.
It is better suited to small and mid-sized pharmaceutical, biotechnology, or medical device companies that do not have a full in-house regulatory team and need temporary or phase-specific access to regulatory experts. It is also suitable for R&D teams preparing for FDA, NMPA, or EMA communications, scientific advice, and eCTD submissions.
The website does not provide information on availability from mainland China, so this can currently only be marked as unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on essentialreg.com official site.
essentialreg.com is an United States SaaS provider. TG4G tracks its product information, an overall rating of 4.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach essentialreg.com directly.